StreetAlpha.app
Home › Stocks › ORIC

Oric Pharmaceuticals, Inc. (ORIC)

Healthcare
$7.36
▼ −4.42%
LAST CLOSE · NOV 20

ORIC Pharmaceuticals develops cancer drug candidates in South San Francisco, led by rinzimetostat for prostate cancer and enozertinib for lung cancer. It last closed at $7.36 on Nov 20, down 4.42% on the day. The next earnings report for ORIC is expected around Mon, Feb 22, 2027, after the close. For the quarter ended Sep 2026, ORIC reported EPS of -$0.44. Over its last 8 reports the stock moved an average of 8.1% the session after earnings. Over the last 12 months ORIC insiders bought $0 of stock on the open market and sold $3.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is ORIC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ORIC.

Key Stats

Last 12 months
Results
Net income
−$155.8M
EPS (diluted)
−$1.44
Free cash flow
−$129.2M
Valuation
Market cap
$764.9M
103.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$33.8M
At Sep 30
Shareholder equity
$339.5M
Shares outstanding
103.9M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$78.7M−$78.7MFY2021FY2022: −$89.1M−$89.1MFY2022FY2023: −$100.7M−$100.7MFY2023FY2024: −$127.8M−$127.8MFY2024FY2025: −$129.5M−$129.5MFY2025

From ORIC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Feb 22
Estimated date · After the close
Reported EPS
-$0.44
Quarter ended Sep 2026
Year ago EPS
-$0.33
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.51Dec '24Mar 2025: -$0.42Mar '25Jun 2025: -$0.47Jun '25Sep 2025: -$0.33Sep '25Dec 2025: -$0.27Dec '25Mar 2026: -$0.34Mar '26Jun 2026: -$0.38Jun '26Sep 2026: -$0.44Sep '26Latest -$0.44
Revenue by quarter
Not enough quarters on file yet.
How ORIC moved after its last 8 reports
Average move the session after a report ±8.1%
Nov 16, 2026After the close+6.4%
Aug 3, 2026After the close+27.1%
May 4, 2026After the close−0.6%
Feb 23, 2026After the close+14.6%
Nov 13, 2025After the close+0.5%
Aug 12, 2025After the close+3.3%
May 5, 2025After the close−11.6%
Feb 18, 2025After the close+1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ORICStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on ORIC: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightTarget cut
Nov 21  
HC WainwrightTarget cut
Nov 20  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on ORIC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ORIC

Technical Analysis

ORIC · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 17% below its 20 day and 51% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the swing low (Jun 3) at $7.32, and the nearest resistance the Pivot at $7.55.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.1%/day
Key levels
$14.6852 week high+99.5%
$11.71100 day average+59.1%
$11.0850 day average+50.5%
$10.92200 day average+48.4%
$8.6320 day average+17.3%
$8.50Swing high (Jun 10)+15.5%
$7.82Pivot R1+6.3%
$7.55Pivot+2.6%
$7.36Last close
$7.32Swing low (Jun 3)−0.5%
$7.2352 week low−1.8%
$7.09Pivot S1−3.7%
Indicators
RSI (14)31.63Weak, oversold below 30Neutral
MACD-1.05Below its signal lineBearish
Stochastic5.4Near the bottom of its rangeOversold
ADX (14)31.4Trending down
Williams %R-97.0Oversold below −80, overbought above −20Oversold
CCI (20)-134.7Oversold below −100, overbought above 100Oversold
Rate of change−16.6%Change over 10 sessionsBearish
ATR (14)$0.74Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ORIC

What happened before

See how ORIC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ORIC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ORIC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ORICHow many large options trades hit ORIC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ORIC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲117 buying vs 74 selling
  • ▼Held by funds -4.6 pts
  • ▲Funds holding +22
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding203181+12.2%
In funds' top 1098+12.5%
Held by funds114.3%118.9%−4.6 pts
New / increased42 / 7529 / 82+5.4%
Reduced / sold out55 / 1942 / 30+2.8%
Put/call ratio0.040.11−63.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ORIC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ORIC Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$3.0M12 sales · 4 insiders
83% of the selling was under pre-arranged trading plans.
2025-12 sold $497K2026-01 sold $80K2026-02 sold $703K2026-07 sold $161K2026-08 sold $1.1M2026-09 sold $189K2026-10 sold $276KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 20Dominic PiscitelliCFOSale plan14,000$13.53$189K
Oct 1Richard A. HeymanDirectorSale plan6,700$12.91$87K
Sep 28Dominic PiscitelliCFOSale plan13,400$13.53$181K
Sep 24Dominic PiscitelliCFOSale plan600$13.50$8K
Aug 26Dominic PiscitelliCFOSale plan77,000$13.69$1.1M
Jul 24Richard A. HeymanDirectorSale plan13,100$12.02$157K
Every insider buy and sale for ORIC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ORIC insider trades →

From SEC Form 4 filings by ORIC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORIC is in one of them and how their past ORIC trades turned out.

ORIC in the AI portfolios
Loading…

ORIC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ORIC in an article yet. Here's the latest on the wider market.

ORIC in the news

About Oric Pharmaceuticals

ORIC Pharmaceuticals is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments designed to counter drug resistance. Its two lead candidates are rinzimetostat, which is being studied in advanced prostate cancer, and enozertinib, which is being studied in lung cancer with certain EGFR gene mutations. Neither candidate has been approved for sale yet.

Headquarters
South San Francisco, CA